All News
Filter News
Found 242 articles
-
bluebird bio to Present Data from Its Severe Genetic Disease and Oncology Portfolios During the EHA2021 Virtual Congress
5/13/2021
bluebird bio, Inc . (Nasdaq: BLUE) announced today that data from its gene therapy programs for transfusion-dependent β-thalassemia (TDT) and sickle cell disease (SCD) and its cell therapy program for relapsed or refractory multiple myeloma (R/RMM) will be presented during EHA2021 Virtual, the 26 th Annual Congress of the European Hematology Association, taking place June 9-17, 2021.
-
Bluebird bio reported first-quarter earnings, the approval of Abecma, the first CAR-T therapy for relapsed or refractory multiple myeloma, and its spinout, 2seventy bio, and its leadership.
-
bluebird bio Reports First Quarter Financial Results and Highlights Operational Progress
5/5/2021
bluebird bio, Inc. reported financial results and business highlights for the first quarter ended March 31, 2021 and shared recent operational progress.
-
Under the terms of the expanded deal, Vertex will be responsible for 60% of the costs of developing, manufacturing and commercializing CTX001 with support from CRISPR Therapeutics, and will receive 60% of profits from global sales.
-
Another bluebird bio executive is jumping ship. Chief Medical Officer David Davidson is leaving the company on April 16.
-
Clinical Catch-Up: March 8-12
3/15/2021
It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson's disease, Alzheimer's, HIV and more. -
EMA Launches Safety Review After Patient of Zynteglo Gene Therapy Trial Develops Blood Cancer
3/12/2021
The European Medicines Agency has launched a safety review of bluebird bio’s thalassaemia drug Zynteglo, a conditionally licensed gene therapy in Europe. -
Recently published data from a mouse model of sickle cell disease (SCD) is bolstering the case for the safety of Cell Source’s CD8+ veto cells, currently in Phase I/II testing to improve peripheral blood stem cell transplantation in patients with hematological malignancies.
-
Preliminary findings of LentiGlobin suggested that the BB305 LVV vector was present in the AML blast cells, but there was not sufficient information to determine causality.
-
bluebird bio Provides Updated Findings from Reported Case of Acute Myeloid Leukemia (AML) in LentiGlobin for Sickle Cell Disease (SCD) Gene Therapy Program
3/10/2021
Analyses demonstrate lentiviral vector BB305 unlikely to be the cause of AML in clinical study of LentiGlobin for SCD bluebird bio has initiated process with regulators to resume clinical studies Company to hold conference call and webcast today, March 10, 2021, 8:00 AM EST
-
The hold comes just after patient dosing began in HGB-210, the company’s Phase III single-arm open-label LentiGlobin trial for SCD patients between the ages of 2 and 50.
-
bluebird bio Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Operational Progress
2/23/2021
bluebird bio, Inc. reported financial results and business highlights for the fourth quarter and full year ended December 31, 2020 and shared recent operational progress.
-
Clinical Catch-Up: February 15-19
2/22/2021
It was a busy week for clinical trial announcements. Here’s a look. -
The Foundation will offer funding for development of the therapy.
-
Bluebird bio announced that it has placed its Phase I/II and Phase III trial of LentiGlobin gene therapy for sickle cell disease (SCD) on temporary suspension.
-
bluebird bio Announces Temporary Suspension on Phase 1/2 and Phase 3 Studies of LentiGlobin Gene Therapy for Sickle Cell Disease (bb1111)
2/16/2021
bluebird bio, Inc. (Nasdaq: BLUE) announced today that the company has placed its Phase 1/2 (HGB-206) and Phase 3 (HGB-210) studies of LentiGlobin gene therapy for sickle cell disease (SCD) (bb1111) on a temporary suspension due to a reported Suspected Unexpected Serious Adverse Reaction (SUSAR) of acute myeloid leukemia (AML).
-
Bluebird bio announced plans to split its genetic disease and oncology businesses. Bluebird bio will stay focused on severe genetic disease and spin out its oncology business into a new company.
-
Errant Gene Therapeutics, LLC (“EGT”) Pushing Clinical Trial of Potentially Curative Treatment for Beta-Thalassemia and Eventually Sickle Cell Disease
1/11/2021
The technology, developed by scientists at Memorial Sloan Kettering Cancer Center ("MSKCC"), headed by Dr. Michel Sadelain and Errant Gene Therapeutics, is a one-time treatment that inserts an encoded gene into a patient's own bone marrow stem cells restoring the production of normal hemoglobin
-
Treatment with Investigational LentiGlobin™ Gene Therapy for Sickle Cell Disease (bb1111) Results in Complete Elimination of SCD-Related Severe Vaso-Occlusive Events in Group C of Phase 1/2 HGB-206 Clinical Study Presented at 62nd ASH Meeting
12/7/2020
No severe vaso-occlusive events (VOEs) reported through 24 months of follow-up in Group C patients who had a history of at least four severe VOEs and at least six months of follow-up (n=19)
-
Magenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magenta’s MGTA-145 for Mobilizing and Collecting Stem Cells in Adults and Adolescents with Sickle Cell Disease
12/4/2020
Magenta Therapeutics (NASDAQ: MGTA) and bluebird bio, Inc. (NASDAQ: BLUE) today announced an exclusive clinical trial collaboration to evaluate the utility of MGTA-145, in combination with plerixafor, for mobilization and collection of stem cells in adults and adolescents with sickle cell disease (SCD).